ArticleWorld journal of nephrology2025
Avacopan in the treatment of relapsing polychondritis with myeloperoxidase-antineutrophil cytoplasmic antibody associated vasculitis: A case report.
Article in World journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis case report describes myeloperoxidase-anti-neutrophil cytoplasmic antibody associated vasculitis with kidney involvement in a patient with relapsing polychondritis, which was successfully treated with Avacopan. Although relapsing polychondritis has been associated with anti-neutrophil cytoplasmic antibody-associated vasculitis, overlap can result in severe organ involvement, particularly renal damage progressing to end-stage kidney disease. This case presents a unique opportunity to evaluate the potential role of Avacopan as an alternative therapeutic option in managing myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated vasculitis in the context of relapsing polychondritis highlighting a positive renal response despite treatment challenges. CASE SUMMARY: This is a case of a 69-year-old Caucasian woman who presented to our hospital's emergency department with a 4 week history of inflammatory polychondritis affecting the auricular cartilage, accompanied by acute kidney injury. On admission, serum creatinine was elevated at 4.0 mg/dL, which progressively increased to 6.07 mg/dL on day 6. The renal biopsy revealed necrotizing and crescentic glomerulonephritis affecting more than 50% of the glomeruli. She was treated with a total of 2500 mg intravenous methylprednisolone over 3 days followed by oral prednisone. Induction treatment included intravenous cyclophosphamide induction, with plans for a total of 2 doses followed by transition to rituximab. However the patient was unable to tolerate rituximab due to allergic reaction so intravenous cyclophosphamide was continued for a total of 6 doses (cumulative dose 3000 mg). In the setting of persistent acute kidney injury, Avacopan was added to the regimen 3 months after diagnosis. Maintenance therapy included azathioprine in addition to Avacopan. Prednisone gradually tapered off at 6 months.
conclusionAvacopan may be beneficial in treating anti-neutrophil cytoplasmic antibody-associated vasculitis with coexisting relapsing polychondritis, especially in cases where preservation of kidney function is critical. Further research will be essential to validate these findings and refine treatment protocols for such complex cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.